Fierce Pharma
OCTOBER 8, 2023
After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. | After years serving as a rumored target of Big Pharma M&A, Mirati Therapeutics has finally made its sale a reality. The buyer, Bristol Myers Squibb, will pay up to $5.8 billion for the KRAS drugmaker.
MedCity News
OCTOBER 8, 2023
The most successful implementations of digital solutions offer value propositions on both sides of the equation — they create value for the patient and family, while also making the clinician’s job easier and more enjoyable by saving time and eliminating ancillary duties.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaTech
OCTOBER 8, 2023
Robotics and isolators are an increasingly popular combination in the pharmaceutical industry due to the rising number of high-value therapies, such as Cell and Gene Therapies.
MedCity News
OCTOBER 8, 2023
Blue Shield of California recently switched up its pharmacy benefit model by distributing responsibilities to several different vendors. The model has the potential to increase drug costs, but it remains to be seen, according to Creagh Milford, SVP of retail health at CVS Health.
PharmExec
OCTOBER 8, 2023
It’s with a heavy heart that I share my departure from Pharmaceutical Executive.® It’s hard to believe that one year ago (in September 2022) I began my journey with the team here and the publication (and with all of you!). First and foremost, a huge thank you to you, the reader, for trusting me to share content with you.
MedCity News
OCTOBER 8, 2023
Takeda Pharmaceutical drug Exkivity failed the confirmatory study required of its 2021 accelerated approval. Our recap of other recent regulatory developments includes a partial clinical hold on a cancer drug, a Covid-19 vaccine authorization, and several drug approvals in the U.S. and beyond.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
OCTOBER 8, 2023
Antisense oligonucleotides (ASOs) have faced their share of challenges, but a combination of research advances and a market ripe for innovation is setting this drug class up for a resurgence. Antisense oligonucleotide (ASO)—a class of drugs that works by targeting RNA to alter gene expression and control aberrant proteins in ways that traditional drugs can’t.
PharmaTech
OCTOBER 8, 2023
Webinar Date/Time: Thu, Oct 26, 2023 11:00 AM EDT
PharmaTech
OCTOBER 8, 2023
Webinar Date/Time: Thu, Nov 2, 2023 2:00 PM EDT
Expert insights. Personalized for you.
246 
Let's personalize your content